Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma
- From the Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1461, Houston, Texas 77030, USA
- (Correspondence should be addressed to M E Cabanillas; Email: mcabani{at}mdanderson.org)
Abstract
In the February 2011 issue of Endocrine-Related Cancer, Deandreis et al. reported that increased FDG uptake was prognostic in patients with metastatic thyroid cancer. Fludeoxyglucose-positron emission tomography (FDG-PET) is routinely used in the staging and follow-up of patients with cancer. This study gives further evidence for the role of FDG-PET scanning in metastatic thyroid cancer, especially to identify patients with aggressive disease requiring systemic therapy.
- Revision received 5 January 2012
- Accepted 11 January 2012
- Made available online as an Accepted Preprint 12 January 2012
- © 2012 Society for Endocrinology
